Portrait of Eiko with a blue gradient and hash pattern overlay

Advancing the Way Heart Failure is Treated

More than 170,000 patients have been supported with Impella® heart pumps

Heart Recovery is Possible With Impella

In a randomized controlled trial, 8-in-10 patients treated with Impella heart pumps experienced reduction in heart failure symptoms or improvement in heart function.2,8 Their native heart function recovered, and heart failure symptoms diminished, such as fatigue, shortness of breath, swelling, and coughing,1,2 in just 90 days after a Protected PCI procedure as compared to other forms of treatment.2 

Start Here

Reduction in Death, Heart Attack and Stroke

in 90-day post-hospitalization as compared to other support methods1

Fewer Repeat Visits

to the hospital for heart-related issues other than traditional therapy3

Fewer Days in the Hospital

after procedure compared to traditional therapy3, 4, 5, 6, 7

Impella is the only U.S. FDA-approved percutaneous heart pump technology indicated for patients with severe coronary artery disease requiring high-risk PCI


Why Impella?

Impella heart pumps have the unique ability to enable heart recovery, allowing patients to return home with their native hearts. Impella is the only non-surgical heart pump that is FDA-approved as safe and effective for high-risk patients receiving a percutaneous coronary intervention (PCI). An Impella-supported stenting procedure, known as Protected PCI, may be an option for you.

Why is Impella Important?

Supports Your Heart

Protected PCI with Impella ensures blood flow is maintained to critical organs enabling your physician to perform a complete and optimized procedure, decreasing the likelihood of repeat procedures and multiple hospital stays.

Improved Quality of Life

In a randomized controlled trial, 8-in-10 patients treated with Impella heart pumps experienced reduction in heart failure symptoms or improvement in heart function.2, 8

Patients Share Their Stories of Heart Recovery


"I really feel 10 years younger!"

Mattie Warren, 77


"Following the procedure, I proudly climbed to the top of the bleachers."

Jim Hoag, 73


"I have never felt better!"

Mary Hanel, 83


What is Protected PCI?

For some patients, their doctors may determine their heart disease is too severe for stenting and too high-risk for surgery. An Impella-supported stenting procedure, also known as Protected PCI, is a nonsurgical, minimally invasive procedure performed in a catheterization lab by an interventional cardiologist. 

During a protected percutaneous coronary intervention (PCI), Impella heart pumps temporarily assist the pumping function of the heart during stent placement to ensure blood flow is maintained to critical organs.  

Improve Your Quality of Life

Protected PCI with Impella can be a safe treatment option to address severe coronary artery disease or advanced heart failure. Answer a few questions to see if you may be a candidate.

Start Here

You are considered a high-risk patient if:

  • Your heart team has told you that angioplasty or stent placement is too risky 
  • There’s nothing more your physician can do to address your symptoms 
  • You are not a candidate for surgery due to your risk factors 
  • You have other health concerns that increase the risk of traditional stenting or heart surgery such as chronic kidney disease 

How Protected PCI Works

The Impella heart pump is inserted through a small incision and advanced through the arteries into the heart. Impella pulls blood from the left ventricle and releases it into the aorta, providing pumping support. This active ‘unloading’ of the left ventricle increases blood flow to vital organs. When support is no longer needed, your cardiologist will remove Impella before you leave the hospital.

Talk to Your Cardiologist

Use this guide to review your treatment options for severe coronary artery disease and/or advanced heart failure.

Find a Hospital

Enter your zip code to find a hospital near you that offers Protected PCI with Impella.


  1. Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228. 
  2. O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.
  3. Gregory, D., et al. (2013). Am Health Drug Benefits, 6(2), 88-99.
  4. Maini, B., et al. (2014). Catheter Cardiovasc Interv, 83(6), E183-E192. 
  5. Gregory, D., et al. (2013). J Manag Care Med, 16(1), 61-69.  
  6. O’Neill, W.W., et al. (2014). J Interviev Cardiol, 27(1), 1-11.
  7. Roos, J.B., et al. (2013). J Med Econ, 16(3), 3381-390.
  8. PROTECT II Data on File